Table 2. Incidence of severe neutropenia among 9,426 HIV-infected patients over a two-year period after ART initiation.
IeDEA West Africa collaboration, 2002–2015.
| Characteristic | No. patients | No. of first neutropenia / PY | Rate (95% CI) per 100 PY | p |
|---|---|---|---|---|
| HIV clinic, Country | <10−4 | |||
| CePReF, Cote d’Ivoire | 3,529 | 481/3,701 | 13.0 (11.9–14.2) | |
| CNTS, Cote d’Ivoire | 1,502 | 141/1,766 | 8.0 (6.8–9.4) | |
| MTCTP, Cote d’Ivoire | 462 | 50/386 | 13.0 (9.8–17.1) | |
| BOBO, Burkina Faso | 1,956 | 93/2,638 | 3.5 (2.9–4.3) | |
| CHUYO, Burkina Faso | 279 | 18/155 | 11.7 (7.3–18.5) | |
| CNHU, Benin | 816 | 46/446 | 10.3 (7.7–13.8) | |
| Gabriel Toure, Mali | 559 | 33/405 | 8.1 (5.8–11.5) | |
| SMITD, Senegal | 323 | 26/228 | 11.4 (7.8–16.8) | |
| Gender | 0.50 | |||
| Male | 2,828 | 265/2,828 | 9.5 (8.4–10.7) | |
| Female | 6,598 | 623/6,923 | 9.0 (8.0–9.7) | |
| Age (years) | 0.39 | |||
| <35 | 4,024 | 364/4,123 | 8.8 (8.0–9.8) | |
| ≥35 | 5,402 | 524/5,601 | 9.3 (8.6–10.2) | |
| Calendar year for ART initiation | <10−4 | |||
| 2002–2005 | 2,259 | 327/2,270 | 14.4 (12.9–16.1) | |
| 2006–2008 | 2,256 | 193/2,485 | 7.8 (5.8–10.3) | |
| 2009–2011 | 2,419 | 190/2,860 | 6.6 (5.0–8.8) | |
| 2012–2014 | 2,492 | 178/2,110 | 8.4 (6.3–11.3) | |
| Baseline neutrophils count (cells/mm3) | <10−4 | |||
| ≥1,300 | 7,944 | 649/8,238 | 7.9 (7.3–8.5) | |
| 1,000–1,300 | 1,034 | 145/1,064 | 13.6 (11.6–16.0) | |
| 750–1,000 | 448 | 94/422 | 22.3 (18.2–27.3) | |
| Baseline hemoglobin level (g/dL) | 0.56 | |||
| ≥10 | 5,974 | 572/6,383 | 9.0 (8.3–9.7) | |
| <10 | 2,936 | 275/2,954 | 9.3 (8.3–10.5) | |
| Missing | 516 | 41/387 | 10.6 (7.8–14.4) | |
| Baseline CD4 count (cells/mm3) | <10−4 | |||
| ≥350 | 1,122 | 56/1,272 | 4.4 (3.4–5.8) | |
| <350 | 7,314 | 753/7,512 | 10.0 (9.3–10.8) | |
| Missing | 990 | 79/941 | 3.7 (2.6–5.2) | |
| Initial ART regimen containing ZDV | <10−4 | |||
| No | 4,345 | 333/4,353 | 7.7 (6.9–8.5) | |
| Yes | 5,081 | 555/5,372 | 10.3 (9.5–11.2) | |
| First-line ART regimen | <10−4 | |||
| ZDV/3TC/EFV | 2,195 | 264/2,281 | 11.6 (10.3–13.1) | |
| ZDV/3TC/NVP | 2,307 | 240/2,433 | 9.9 (8.7–11.2) | |
| D4T/3TC/EFV | 819 | 86/833 | 10.3 (8.4–12.8) | |
| D4T/3TC/NVP | 1,426 | 127/1,446 | 8.8 (7.4–10.5) | |
| TDF-based regimens | 1,590 | 85/1,542 | 5.5 (4.5–6.8) | |
| Other regimens | 1,089 | 86/1,189 | 7.2 (5.9–8.9) | |
| Baseline clinical stage (CDC 3 or WHO 4) | <10−3 | |||
| No | 5,930 | 527/6,184 | 8.5 (7.8–9.3) | |
| Yes | 1,557 | 184/1,552 | 11.9 (10.3–13.7) | |
| Missing | 1,939 | 177/1,988 | 8.9 (7.7–10.3) | |
PY, person-year; CI, confidence interval; ART, antiretroviral therapy; CDC, US Centers for Disease Control; WHO, World Health Organization; ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; TDF, tenofovir; FTC, emtricitabine; CTX, cotrimoxazole.